New
Product: Lantus In A Pen
Aventis Submits OptiClik™ LantusInsulin Delivery Device for Approval
Aventis
announced that it has submitted marketing applications in Europe and
the United States for the new OptiClik™, a reusable pen for administering
Lantus® (insulin glargine [rDNA origin] injection). The cartridge
for the OptiClik™, has also been submitted to the regulatory authorities
in Japan.
“The
OptiClik™ follows more than two years of investment in developing
a delivery device to help meet the needs of people with diabetes,”
explains Volker Keuth, Head of Medical Devices at Aventis in Frankfurt.
The OptiClik™ will provide patients with a new easy to use delivery
option and will be used with Lantus®, the 24-hour basal insulin
analogue, and is planned to be submitted for use with Apidra™
(insulin glulisine [rDNA origin] injection), Aventis’ rapid-acting
insulin analogue.
Back to Main Page
